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Abstract 
Background: Platelet-derived microvesicles (PMVs), shed from platelet surface membranes, constitute the 
majority of circulating microvesicles and have been implicated in procoagulant, pro-inflammatory and 
pro-atherosclerotic effects. Our aim was to compare plasma PMVs numbers in relation to platelet reactivity 
during dual antiplatelet therapy (DAPT) with various P2Y12 adenosine diphosphate (ADP) receptor antagonists.  
Methods: In pre-discharge men treated with DAPT for an acute coronary syndrome, plasma PMVs were 
quantified by flow cytometry on the basis of CD62P (P-selectin) and CD42 (glycoprotein Ib) positivity, putative 
indices of PMVs release from activated and all platelets, respectively. ADP-induced platelet aggregation was 
measured by multiple-electrode aggregometry.  
Results: Clinical characteristics were similar in patients on clopidogrel (n=16), prasugrel (n=10) and ticagrelor 
(n=12). Platelet reactivity was comparably reduced on ticagrelor or prasugrel versus clopidogrel (p<0.01). 
Compared to clopidogrel-treated patients, CD42+/CD62P+ PMVs counts were 3-4-fold lower in subjects 
receiving ticagrelor (p=0.001) or prasugrel (p<0.05), while CD42+ PMVs were significantly reduced on 
ticagrelor (by about 6-fold, p<0.001), but not prasugrel (p=0.3). CD42+/CD62P+ PMVs numbers correlated 
positively to the ADP-induced aggregation on clopidogrel (p<0.01) or prasugrel (p<0.05), which was absent in 
ticagrelor users (p=0.8). CD42+ PMVs counts were unrelated to platelet reactivity (p>0.5).  
Conclusions: Higher antiplatelet potency of prasugrel and ticagrelor versus clopidogrel is associated with 
decreased plasma CD42+/CD62P+ PMVs numbers. However, in contrast to thienopyridines, the association of 
reduced CD42+/CD62P+ PMVs counts with ticagrelor use appears independent of its anti-aggregatory effect. 
Despite similar platelet-inhibitory activity of ticagrelor and prasugrel, only the treatment with ticagrelor seems 
associated with lower total PMVs release. Our preliminary findings may suggest a novel pleiotropic effect of 
ticagrelor extending beyond pure anti-aggregatory properties of the drug. 
Key words: dual antiplatelet therapy; P2Y12 antagonists; platelets; microvesicles; ticagrelor 
Introduction 
Dual antiplatelet therapy (DAPT) with low-dose 
aspirin and a P2Y12 adenosine diphosphate (ADP) 
receptor antagonist is a standard of care in patients 
with acute coronary syndromes (ACS) and after 
coronary stenting. Although clopidogrel, prasugrel 
and ticagrelor are all treatment options, ticagrelor is a 
preferential drug in ACS patients treated with 
percutaneous coronary stent implantation, and those 
with medically managed ACS without persistent 
ST-segment elevation [1-3]. The Platelet Inhibition 
and Patient Outcomes (PLATO) trial demonstrated 
lower risk of all-cause mortality, cardiovascular (CV) 
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mortality, myocardial infarction and definite stent 
thrombosis in ACS subjects randomized to ticagrelor 
compared to clopidogrel for 12 months, regardless of 
ST-segment elevation and treatment strategy [4]. The 
clinical benefits of ticagrelor, a non-thienopyridine 
antagonist of P2Y12 receptors, have traditionally been 
ascribed to its ability to rapidly block platelet P2Y12 
receptors with a more consistent platelet inhibition 
than that achieved with thienopyridines [5]. 
Additionally, ticagrelor, in contrast to 
thienopyridines, does not require previous hepatic 
metabolic activation and binds reversibly to P2Y12 
receptors. Recently, it has been suggested that 
mechanisms of clinical benefits of ticagrelor may 
extend beyond pure blockade of platelet P2Y12 
receptors [5-7].  
Membrane-coated platelet-derived microvesicles 
(PMVs), irregularly shaped and ranging in size from 
0.1 to 1 μm, constitute the majority of circulating 
microvesicles (MVs), and are released by surface 
membrane shedding accompanying platelet 
activation [8-10]. Notably, an ex vivo study 
demonstrated that about 23−40% of the procoagulant 
activity of human platelet suspensions appeared 
associated with PMVs [11]. Besides providing an 
additional anionic surface for coagulation, including 
procoagulant activity at a distance from the site of 
platelet activation, PMVs have been implicated in 
pro-inflammatory and pro-atherosclerotic effects 
[10,12-14]. Elevated numbers of plasma PMVs were 
described in patients with clinical atherosclerotic CV 
disease or risk factors, which has been linked to 
chronic platelet activation [10,12]. In ACS, PMVs 
counts are several-fold elevated and rapidly fall after 
initiation of clopidogrel-based DAPT, generally 
following the pattern of platelet activation [15,16]. 
Previous studies in patients receiving 
clopidogrel-based DAPT revealed an association 
between platelet aggregability and PMVs release, i.e. 
increased pre-discharge PMVs counts in ACS patients 
with high on-treatment platelet reactivity [17,18].  
To the best of our knowledge, circulating PMVs 
have not been measured in ACS subjects treated with 
prasugrel or ticagrelor [14]. Very recently, Gąsecka et 
al. [19] demonstrated the capability of ticagrelor, 
added to platelet-rich plasma obtained from healthy 
volunteers, to inhibit in vitro PMVs generation in 
response to ADP, nevertheless, that study has been 
focused on the release of PMVs from ADP-stimulated 
platelets.  
Therefore, our aim was to compare the number 
of plasma PMVs in relation to platelet reactivity in 
ACS patients on DAPT with ticagrelor and 
thienopyridine P2Y12 receptor antagonists. 
Materials and Methods 
Patients 
 We studied 38 men, aged 45−75 years, admitted 
to our department for an ACS who underwent 
invasive management. DAPT was initiated at 
admission before coronary angiography according to 
practice recommendations [1-3] and included 
ticagrelor (loading dose [LD]: 180 mg followed by a 
maintenance dose [MD] of 90 mg twice daily), 
prasugrel (LD: 60 mg, MD: 10 mg once daily in the 
morning) or clopidogrel (LD: 600 mg; MD: 75 mg once 
daily in the morning), in addition to low-dose aspirin 
(75−100 mg once daily in the morning). Patients with 
a history of previous ACS, coronary revascularization 
or DAPT prior to the index hospitalization, a 
complicated in-hospital course or left ventricular 
ejection fraction ≤35% (by echocardiography), 
significant valvular heart disease, relevant coexistent 
diseases (except for well-controlled diabetes and 
hypertension), and those with significant 
abnormalities in routine blood or urine assays, had 
been excluded. Besides DAPT, all the study subjects 
were receiving standard medical therapy, i.e. an 
angiotensin-converting enzyme inhibitor (ACEI) and 
a statin. 
Blood for PMVs assay and the ADP-induced 
platelet aggregation was drawn from an antecubital 
vein on the last day of hospitalization, after an 
overnight fast before administration of the morning 
dose of drugs, at routine pre-discharge blood 
sampling. We used a 20-gauge needle, and a light 
tourniquet was released promptly after the 
appearance of freely flowing blood in the plastic 
collection tube.  
Platelet pre-activation was prevented by 
discarding the first 2−3 ml of blood. Blood for PMVs 
assay was collected to plastic tubes with potassium 
ethylenediaminetetraacetic acid (EDTA) (final 
concentration: 1.6 mg EDTA per mL of blood), mixed 
gently and centrifuged at room temperature for 10 
min at 2700 g (Thermo Scientific Heraeus Labofuge 
200, Newtown, CT, USA), with a similar delay (30 
min) between blood sampling and the centrifugation 
step. Then plasma was separated, frozen at −80oC and 
stored until assayed. The university ethics committee 
had approved the study (KBET/277/B/2013) and 
patients gave written informed consent. 
ADP-induced platelet aggregation 
Multiple electrode aggregometry was used to 
estimate platelet reactivity (Multiplate analyzer, 
Dynabyte, Munich, Germany). This method is based 
on elevated electrical impedance owing to platelet 
adhesion to the surface of a sensor wire [20]. As 
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described previously [21,22], immediately after blood 
sampling, thrombin inhibitor-anticoagulated blood 
was diluted with 0.9% NaCl (1:2) and stirred at 37oC 
for 3 min. Then, we added ADP in a final 
concentration of 6.4 mmol/L. ADP-induced platelet 
aggregation was quantified as the area under the 
curve (in arbitrary units [AU] x min), representing 
increases in electrical impedance in the function of 
time during a 6-min recording [20]. 
Enumeration of PMVs 
PMVs were enumerated in stored plasma 
samples. Before analysis, samples were thawed at 
37oC in a water bath to avoid cryoprecipitation and 
then elaborated and prepared for MVs assay as 
described previously [16]. In particular, after thawing, 
samples were centrifuged once for 15 min at 2500 g, to 
remove residual platelets. All analyses were 
performed by means of the Apogee A50 micro flow 
cytometer (Apogee Flow Systems Ltd., Northwood, 
UK) (Figure 1) for 180 s with a flow rate of 1.5 
µL/min; the sample volume was set at 150 µL and the 
sheath pressure at 150 hPa. As the first, the average 
events count was measured and appropriate dilutions 
were performed in order to obtain 5000 events/s. 
PMV staining was performed in 20 µL of a plasma 
sample by the incubation with previously chosen 
antibodies against platelet surface markers 
CD42(b)/CD62P: a mixture of 1 μL phycoerythrin 
(PE) anti-human CD42(b) Antibody (BioLegend, San 
Diego, CA, USA) and 1 μL of Alexa Fluor® 647 
anti-human CD62P antibody (BioLegend) (Figure 1C), 
and isotype control (1 µL of Alexa Fluor® 647 Mouse 
IgG1, κ Isotype Ctrl (FC) Antibody) (BioLegend) 
(Figure 1D). To count entire numbers of MVs, a 
portion (20 µL) of each sample was stained with 1 µL 
of annexin V, binding to membrane 
phosphatidylserine (PS), expressed on the surface of 
MVs irrespective of their origin (fluorescein 
isothiocyanate [FITC] Annexin V; Annexin V Binding 
Buffer, BioLegend) (Figure 1B), After 30 minutes of 
incubation, samples were diluted in 
phosphate-buffered saline to obtain a final volume of 
200 µL. The trigger was set on a middle angle light 
scattering (MALS) detector with a voltage of 415 V. 
For daily calibration, we used the reference beads 
(Figure 1A) (ApogeeMix, cat#1493, Apogee Flow 
Systems Ltd.) composed of a mixture of 180 nm, 240 
nm, 300 nm, 590 nm, 880 nm, and 1300 nm silica 
vesicles with a refractive index of 1.43, and 110-nm 
and 500-nm green fluorescent (excited by blue laser) 
latex beads with a refractive index of 1.59. Final 
results were corrected by a dilution factor. 
 
 
Figure 1. Flow cytometry analysis of platelet-derived microvesicles (PMVs) and microvesicles (MVs) with the Apogee A50-Micro flow cytometer. Data were collected on middle 
angle light scattering. Dot plots present: (A) calibration beads; (B) MVs stained with annexin V-FITC; (C) PMVs stained with anti-CD42-PE and anti-CD62P Alexa Fluor 647; (D) 
isotype control for anti-CD62P. FITC: fluorescein isothiocyanate; PE: phycoerythrin. 
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Statistical analysis 
Patients’ characteristics are presented as means 
and SD or n (%). Due to a non-Gaussian distribution, 
MVs/PMVs counts and platelet reactivity were 
shown as median and interquartile or absolute range. 
The significance of intergroup differences was 
assessed by analysis of variance (ANOVA) or 
Kruskal-Wallis ANOVA (followed by Mann-Whitney 
U test) for normally or non-normally distributed 
continuous data, respectively, and the chi-squared 
test for categorical characteristics. Bivariate relations 
of platelet aggregability to plasma counts of PMVs 
and MVs were estimated by Pearson’s correlation 
coefficients (r) after logarithmic transformation to 
obtain a normal distribution. Mann-Whitney U test 
was applied to compare numbers of PMVs or MVs in 
patients with an above-median ADP-induced platelet 
aggregation relative to those with platelet reactivity 
lower than the respective median, calculated 
separately for patients treated with clopidogrel, 
prasugrel and ticagrelor. A p-value below 0.05 was 
assumed significant. 
Results  
Patients’ clinical and biochemical characteristics 
were similar in patients treated with clopidogrel, 
prasugrel and ticagrelor (Table 1). 
Ex vivo platelet reactivity in response to ADP 
was reduced to a similar degree in patients treated 
with ticagrelor (median [interquartile range]: 152 
[94−190] AU x min, p<0.01) or prasugrel (151 
[104−203] AU x min, p<0.01) versus clopidogrel (266 
[168−374] AU x min) (Figure 2). 
 
Table 1. Patients’ characteristics by the use of ticagrelor and 
thienopyridine P2Y12 antagonists. 
Characteristic P2Y12 receptor antagonist 
Clopidogrel 
n=16 
Prasugrel 
n=10 
Ticagrelor 
n=12 
Age, years 63 ± 10 63 ± 10 64 ± 9 
Body-mass index, kg/m2 28.5 ± 5.1 26.3 ± 4.5 29.6 ± 3.5 
Diabetes, n (%) 3 (19%) 2 (20%) 2 (17%) 
Hypertension, n (%) 13 (81%) 7 (70%) 8 (67%) 
GFR, mL/min per 1.73 m2 77 ± 18 80 ± 17 77 ± 22 
LDL cholesterol, mmol/L 2.6 ± 0.8 2.7 ± 0.9 2.6 ± 0.8 
HDL cholesterol, mmol/L 1.0 ± 0.3 1.1 ± 0.3 1.0 ± 0.4 
Triglycerides, mmol/L 1.6 ± 0.6 1.7 ± 0.6 1.6 ± 0.6 
Ejection fraction, % 50 ± 12 48 ± 8 51 ± 12 
Platelets, 103/uL 245 ± 97 205 ± 57 201 ± 65 
Erythrocytes, 106/uL 4.5 ± 0.6 4.4 ± 0.5 4.3 ± 0.6 
Leukocytes, 103/uL 9.5 ± 2.5 9.0 ± 2.4 8.4 ± 1.9 
Hemoglobin, g/dL 13.5 ± 1.7 14.0 ± 1.3 13.3 ± 2.0 
Medication, n (%) 
(besides DAPT+ACEI+statin) 
   
 β-blocker 13 (81%) 10 (100%) 11 (92%) 
 Diuretic 6 (38%) 4 (40%) 4 (33%) 
 Calcium channel blocker 2 (13%) 1 (10%) 2 (17%) 
Hospitalization length, days 5 ± 2 4 ± 2 5 ± 2 
Data are shown as mean and SD or n (%). 
Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; DAPT: dual 
antiplatelet therapy; GFR: glomerular filtration rate; HDL: high-density 
lipoproteins; LDL: low-density lipoproteins. 
 
Plasma counts of CD42/CD62P double-positive 
PMVs were about 3-4-fold lower in subjects receiving 
ticagrelor (128 [78−133] per μL, p=0.001) or prasugrel 
(142 [87−238] per μL, p<0.05) compared with 
clopidogrel users (474 [181−1330] per μL) (Figure 3). 
CD42-positive PMVs were significantly decreased in 
patients treated with ticagrelor (5.7 [4.2−6.6] 103/μL, 
p<0.001), but not prasugrel (23.8 [16.9−50.6] 103/μL, 
p=0.3), in comparison with those on clopidogrel (37.2 
[21.8−93.3] 103/μL) (Figure 4).  
 
 
Figure 2. Platelet reactivity on ticagrelor and thienopyridine P2Y12 antagonists. Data are shown as median and interquartile range. ADP: adenosine diphosphate; AU: arbitrary 
units. 
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Figure 3. Plasma counts of CD42+/CD62P+ platelet-derived microvesicles (PMVs) on ticagrelor and thienopyridine P2Y12 antagonists. Data are shown as median and 
interquartile range. 
 
Figure 4. Plasma counts of CD42+ platelet-derived microvesicles (PMVs) on ticagrelor and thienopyridine P2Y12 antagonists. Data are shown as median and interquartile range. 
 
Among CD42+ PMVs, the proportion of 
CD42+/CD62P+ PMVs was elevated (p<0.05) in the 
ticagrelor group (2.0 [1.3−2.7] %) versus prasugrel (0.8 
[0.5−1.3] %) or clopidogrel (1.3 [0.7−1.8] %), mainly 
due to over 6-fold reductions of CD42+ PMVs on 
ticagrelor.  
CD42+/CD62P+ PMVs numbers correlated 
positively to the ADP-induced platelet aggregation in 
patients on either clopidogrel (r = 0.60, p<0.01) or 
prasugrel (r = 0.65, p<0.05), which was absent on 
ticagrelor (r = 0.1, p=0.8) (for log-transformed values). 
Accordingly, CD42+/CD62P+ PMVs counts were 
significantly higher (p<0.05; p=0.01) in patients with 
above-median platelet aggregability only in those 
receiving thienopyridine P2Y12 receptor antagonists 
(Table 2). Platelet reactivity was unrelated to either 
CD42+ PMVs or total MVs numbers (p>0.5).  
Discussion 
We found about 3-4-fold lower pre-discharge 
numbers of plasma CD42/CD62P double-positive 
PMVs, in CAD patients receiving DAPT comprising 
of ticagrelor or prasugrel in addition to aspirin, 
compared with their counterparts on the 
clopidogrel-based DAPT. However, despite similar 
inhibition of the ADP-induced ex vivo platelet 
aggregation on prasugrel and ticagrelor, a positive 
relationship between platelet reactivity and counts of 
CD42+/CD62P+ PMVs, originating presumably from 
activated platelets, was observed only in subjects 
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treated with clopidogrel or prasugrel, being absent in 
ticagrelor users. Notably, plasma CD42-positive 
PMVs numbers, putatively reflecting total PMVs 
release, were significantly reduced only on ticagrelor 
(by about 6-fold), but not on prasugrel. 
 
Table 2. Plasma platelet-derived microvesicles (PMVs) counts by 
platelet reactivity on ticagrelor and thienopyridine P2Y12 
antagonists. 
P2Y12 receptor antagonist ADP-induced platelet aggregation 
below-median above-median 
 CD42+/CD62P+ PMVs [per μL] 
Clopidogrel 181 [78−516] 1329 [256−4556]** 
Prasugrel 87 [33−238] 167 [133−489]* 
Ticagrelor 117 [30−244] 128 [67−133] 
 CD42+ PMVs [103/μL] 
Clopidogrel 27.0 [6.9−132.6] 58.2 [18.9−614.8] 
Prasugrel 16.9 [2.6−34.5] 26.0 [9.2−85.1] 
Ticagrelor 5.4 [3.0−7.7] 6.0 [2.9−7.1] 
Data are shown as median and range. 
**p=0.01, *p<0.05 versus patients with below-median ADP-induced platelet 
aggregation. 
Median ADP-induced platelet aggregation was 248, 151 and 152 AU x min in 
patients receiving clopidogrel, prasugrel and ticagrelor, respectively.  
Abbreviations: ADP: adenosine diphosphate; AU: arbitrary units. 
 
Mechanisms of PMVs formation and their 
procoagulant activity 
PMVs, described for the first time in 1967 by 
Peter Wolf [23] and termed “platelet dust” has 
re-gained attention on the basis of accumulating 
evidence. First, Sims et al. [24] demonstrated that an 
impaired capacity to generate PMVs upon activation 
may underlie defective platelet function in Scott 
syndrome, a congenital bleeding disorder. Second, 
Tans et al. [11] described the 18−28% contribution of 
PMVs to both procoagulant and anticoagulant activity 
of human platelets stimulated with various platelet 
agonists. Furthermore, the percentage was even 
higher in unstimulated platelets (28−40%) [11]. 
Formation of PMVs is temporally related to the 
translocation of aminophospholipids (PS and 
phosphatidyletanolamine, preferentially localized to 
the inner leaflet of the membrane bilayer in normal 
conditions) into the outer leaflet. Platelet vesiculation 
requires not only the disruption of the asymmetric 
distribution of aminophospholipids, but also 
reorganization of the cytoskeleton, both of which are 
mediated by elevations in intraplatelet Ca2+ activating 
scramblase and cytosolic calpain, respectively [10,12].  
Importantly, owing to exposure of negatively 
charged PS, PMVs possess high-affinity binding sites 
for coagulation factors, including factor Va, VIIIa, IXa 
[12] with a 13-fold higher surface density of factor Xa 
compared to activated platelets [25], enabling the 
assembly of intrinsic tenase (factor IXa/VIIIa) and 
prothrombinase (factor Xa/Va) complexes, thereby 
amplifying both tissue factor (TF)-independent and 
TF-dependent coagulation pathways [12]. 
Additionally, surface densities of β3-integrin (CD61, a 
component of the GPIIb/IIIa complex) and P-selectin 
(CD62P) were about 8-fold and 4-fold higher for 
PMVs than for activated platelets, which accounted 
for 50−100-fold greater procoagulant activity of 
PMVs, when computed per unit of surface area [25]. 
Finally, compared to platelets, the procoagulant 
activity of PMVs lasts longer and may be exerted 
distantly from the site of platelet activation [12]. 
Intraplatelet Ca2+ concentrations, governing 
platelet vesiculation, are increased by various platelet 
agonists binding to their respective receptors. Higher 
Ca2+ levels induce platelet shape changes, trigger the 
secretion of alpha and delta (dense) granules, and 
thromboxane A2 (TXA2) synthesis. ADP, released 
from dense granules, and TXA2 are secondary 
mediators of aggregation. ADP amplifies activation 
and aggregation acting on both P2Y1 and P2Y12 
receptors. P2Y1 receptors are linked to intraplatelet 
Ca2+ mobilization via phospholipase C activation. In 
contrast, P2Y12 signaling results in the inhibition of 
adenylate cyclase and activation of 
phosphatidylinositol 3-kinase (PI3K) [26]. These 
pathways, together with Ca2+ elevations, further 
potentiate granules secretion and conformational 
changes in fibrinogen receptor (GPIIb/IIIa), which 
enables binding of fibrinogen with platelet 
cross-linking and irreversible aggregation. 
Additionally, procoagulant activity is also enhanced 
with consequent thrombin generation, formation of 
fibrin and thrombus stabilization. Of note, the 
P2Y12-mediated pathway indirectly contributes to 
Ca2+ mobilization not only through potentiated 
release of ADP and its binding to P2Y1, but also via 
PI3K activation and lowering of intraplatelet cyclic 
adenosine 3’,5’-monophosphate (cAMP), thereby 
augmenting P2Y1-dependent effects [26].  
Accordingly, the joint effects of P2Y1 and 
P2Y12-dependent signaling control the initiation and 
amplification of the ADP-induced aggregation, 
respectively, and also accelerate aggregation and 
thrombus formation induced by other agonists via 
multiple positive feed-forward loops, including 
potentiation of procoagulant activity by PMVs 
generation.  
Comparison with previous studies 
The observed association between the numbers 
of plasma CD42+/CD62P+ PMVs and the 
ADP-mediated platelet aggregation in patients treated 
with clopidogrel or prasugrel was not unexpected 
because surface expression of CD62P, stored in alpha 
granules, appears on activated platelets. However, it 
is noteworthy that circulating PMVs counts and the 
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ADP-induced platelet aggregation were correlated 
only in subjects on a thienopyridine P2Y12 receptor 
antagonist, being yet unrelated in ticagrelor users. The 
latter finding appears counterintuitive because 
positive associations between ex vivo platelet 
aggregability and in vivo blood PMVs counts could be 
suspected from previous studies, reporting elevated 
pre-discharge PMVs numbers in ACS patients with 
higher on-treatment platelet reactivity on DAPT 
comprising of aspirin and clopidogrel [17,18]. In 
addition, a negative correlation between PMVs 
numbers and plasma concentrations of clopidogrel in 
stable CAD patients receiving clopidogrel and aspirin 
was also consistent with that concept [27].  
On the other hand, circulating PMVs in subjects 
treated with prasugrel or ticagrelor have not been 
estimated so far, to the best of our knowledge [14]. 
Moreover, in vivo comparisons of blood PMVs counts 
between patients on various P2Y12 antagonists have 
not been reported yet. Admittedly, Behan et al. [28] 
observed that cangrelor not only more effectively 
decreased platelet aggregation, but also yielded more 
extensive inhibition of intraplatelet Ca2+ elevations 
and PMVs formation in response to thrombin 
receptor-activating peptide in vitro, which contrasted 
with only partial inhibition of these effects estimated 
ex vivo in platelet-rich plasma isolated from patients 
on clopidogrel and aspirin. Additionally, similar to 
the prasugrel active metabolite, cangrelor also 
potently blocked phenomena associated with the 
agonist-induced platelet activation in vitro, i.e. Ca2+ 
mobilization, procoagulant activity (reflected by PS 
exposure) and PMVs generation [29]. Very recently, in 
an vitro study, Gąsecka et al. [19] described an ability 
of ticagrelor to induce interrelated inhibition of the 
ADP-induced platelet aggregation and the 
ADP-mediated release of PMVs from activated 
platelets (defined as CD61(GPIIIa)/CD62P/PS 
triple-positive MVs). However, all those studies 
[19,28,29] were focused on PMVs generation in 
response to platelet agonists, not on resting PMVs 
counts in plasma. So, although stronger P2Y12 
blockers more efficiently counteract agonists-induced 
platelet aggregation and PMVs generation in vitro, 
this notion may not necessarily imply analogous 
results with regard to circulating PMVs. 
Hypothetical mechanisms of different 
relations between PMVs counts and platelet 
reactivity in patients receiving ticagrelor and 
thienopyridine P2Y12 receptor antagonists 
This finding can result from differences in 
pharmacokinetics and pharmacodynamics between 
ticagrelor and thienopyridine P2Y12 receptor 
antagonists. Ticagrelor, contrary to thienopyridines 
whose active metabolites are detected in the systemic 
blood only for about 4 h after prodrug intake, allows a 
constant plasma exposure of an active compound 
over 24 h [5]. Therefore, newly-generated immature 
platelets, known to be associated with CV risk [30], 
are rapidly inhibited in ticagrelor users. In contrast, in 
patients on a thienopyridine P2Y12 receptor 
antagonist, juvenile platelets remain active until the 
next prodrug intake, if they have been formed after 
the elimination of the active metabolite [5]. At later 
time points after clopidogrel intake, but not after 
ticagrelor, Kuijpers et al. [31] demonstrated, in an 
experimental study, a gradually emerging 
subpopulation of uninhibited newly-formed platelets 
which preferentially contributed to augmented 
thrombus formation on collagen under high 
shear-stress conditions. More recently, a 2-fold lower 
inhibition of immature platelets in prasugrel-treated 
than ticagrelor-treated ACS patients was shown late 
after the last drug intake, i.e. 1 h before the next dose 
[32]. Because the consequent differences in 
anticoagulant potency between clopidogrel and 
ticagrelor were not detected by conventional platelet 
aggregation assays [31], this juvenile 
platelets-mediated effect was presumably also 
masked in our patients, whose blood was sampled 
before the morning drug dose. Therefore, it can by 
hypothesized that a stronger ability of ticagrelor than 
prasugrel to inhibit juvenile platelets in vivo might 
have translated into lower circulating PMVs, but was 
missed by the ADP-induced platelet aggregation, 
thereby obscuring the association of PMVs and 
platelet reactivity in patients on ticagrelor.  
Second, under a strong and constant P2Y12 
blockade, as in patients receiving ticagrelor, 
P2Y12-dependent platelet responses to ADP are 
presumably profoundly inhibited, including the 
ability to potentiate P2Y1-dependent Ca2+ elevations 
[26], and amplification of platelet 
activation/aggregation evoked by other stimuli. 
Increases in intracellular Ca2+ levels are also pivotal 
for the release of PMVs from platelets stimulated by 
soluble agonists [33,34] and high shear-stress [35,36]. 
In contrast, shedding of PMVs from unstimulated 
platelets is governed by Ca2+-independent pathways 
[37]. Indeed, PMVs formation in suspensions of 
unstimulated platelets was not dependent on 
intracellular Ca2+ elevation or calpain activation, and 
appeared to be mediated by so-called “outside-in” 
GPIIb/IIIa signaling [37]. So, Ca2+-independent 
pathways of PMVs release may be relatively more 
important for plasma PMVs counts in patients on 
ticagrelor, thereby explaining a lack of correlation 
between blood PMVs and platelet reactivity to ADP in 
our ticagrelor-treated CAD patients. Additionally, 
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only about 20% of PMVs released by unstimulated 
platelets exposed PS, mediating phospholipid- 
dependent procoagulant activity of PMVs [38]. This 
observation is consistent with a minimal level of 
activation of unstimulated platelets generating PMVs 
in stored platelet-rich plasma, with a 5−8% expression 
of PS and activated GPIIb/IIIa, unlike ADP-activated 
platelets expressing almost 100% of these surface 
markers [37]. Thus., the predominance of 
non-activated platelets in ticagrelor users could 
contribute to the lack of correlation between in vitro 
ADP-induced platelet aggregation and in vivo PMVs 
counts on ticagrelor. The suggested hypothetical 
explanation for the dissociation of blood PMVs counts 
and platelet reactivity is in analogy to that proposed 
for a lack of association between solid cerebral 
microembolic signals on transcranial Doppler 
ultrasonography and blood PMVs, coagulation 
parameters or platelet activity in patients with a 
mechanical heart valve on oral anticoagulation [39]. 
The authors suggested that even if a non-significant 
increase in PMVs might have reflected enhanced 
platelet activation, it probably did not reach the 
irreversible phase of platelet aggregation [39]. 
Third, a dissociation of plasma PMVs counts and 
ADP-induced aggregation on ticagrelor, but not on 
thienopyridines, could result from the potentiation of 
the anti-platelet effect of ticagrelor by endogenous 
mediators such as nitric oxide (NO), which was 
reflected by circulating PMVs counts (a measure of in 
vivo platelet activation and associated PMVs release), 
but not by ex vivo testing of platelet reactivity. A 
similar concept was proposed by Chan et al. [40] to 
explain the lack of prognostic benefits from ex vivo 
monitoring of platelet aggregability and subsequent 
tailoring of DAPT intensity. P2Y12 receptor blockade 
strongly increases the ability of endogenous nitric 
oxide (NO) and prostacyclin (PGI2) to attenuate 
platelet reactivity [41,42], and NO and PGI2 further 
synergistically inhibit platelet activation via 
interactions between their respective second 
messengers, cyclic guanosine 3’,5’-monophosphate 
(cGMP) and cAMP [43]. On the other hand, although 
improvement of endothelial function was reported 
after ticagrelor in comparison with thienopyridines in 
stable post-ACS patients [44,45], this finding was yet 
not confirmed in a recent study by Ariotti et al. [46].  
As to adenosine, ticagrelor, in addition to 
binding to P2Y12 receptors, reduces cellular uptake od 
adenosine and increases its extracellular 
concentrations in humans [47], owing to the 
drug-induced inhibition of equilibrative nucleoside 
transporter-1 [6]. Adenosine – via platelet A2A and 
A2B receptors – activates adenylate cyclase and 
down-regulates P2Y1 receptor expression [48], 
inhibiting platelet aggregation and attenuating Ca2+ 
elevations both directly, acting on P2Y1 [26], and 
indirectly, modulating the P2Y12-mediated 
amplification of P2Y1-dependent effects [26]. 
Intraplatelet Ca2+ governs PMVs shedding from 
activated platelets [33,34]. Therefore, the 
ticagrelor-induced accumulation of adenosine, a 
cAMP “elevator”, may strengthen the above 
presented hypothesis of synergistic interactions 
between P2Y12 antagonism, intraplatelet cAMP and 
cGMP [40,43] in circulating platelets. These 
interactions might be an explanation for the 
dissociation of ex vivo platelet reactivity and 
circulating CD42+/CD62P+ PMVs counts, integrating 
also possible in vivo effects of endogenous NO, PGI2 
and adenosine on PMVs release in patients receiving 
ticagrelor, in contrast to thienopyridine P2Y12 
antagonists. 
Irrespective of the mechanisms involved, the 
independence of in vivo PMVs release and ex vivo 
platelet reactivity on ticagrelor may not only reflect 
the in vivo amplification of the drug-specific 
inhibition of platelet activation and associated PMVs 
shedding, but could also add to ticagrelor pleiotropic 
effects, including prevention of systemic 
inflammatory activation and, importantly, reduced 
risk of adverse CV events. 
Depressed plasma counts of PMVs – a novel 
pleiotropic effect of ticagrelor ? 
Biological effects of PMVs extend beyond blood 
coagulation. PMVs promote formation of 
platelet/PMVs/leukocyte aggregates and facilitate 
leukocyte tethering to activated endothelia, providing 
a basis for the contribution of PMVs to 
pro-inflammatory and pro-atherosclerotic responses 
[10,12-14]. These effects have been accounted for by a 
corollary of pathways, e.g. surface expression of GPIb 
(a counter-receptor for the leukocyte β2-integrin 
CD11b/CD18, i.e. Mac-1), P-selectin (binding to 
P-selectin glycoprotein ligand-1 on leukocytes 
[PSGL-1]) and CD40L, a ligand for leukocyte Mac-1 
and CD40 on antigen-presenting dendritic cells, 
B-cells and endothelial cells. Notably, the 
P-selectin−PSGL-1 interaction also contributes to the 
delivery of TF from TF-exposing monocytes into 
developing platelet thrombus via monocyte-derived 
MVs bearing both PSGL-1 and TF [12,49]. Other 
pro-inflammatory pathways include transcellular 
transfer of arachidonic acid, a substrate for 
cyclooxygenase-2, with subsequent upregulation of 
intercellular adhesion molecule-1 (ICAM-1) and 
β2-integrins on endothelial cells and monocytes, 
respectively [50], conversion of pentameric C-reactive 
protein to its highly pro-inflammatory monomeric 
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form [51], and enhancement of endothelial 
adhesiveness for neutrophils via interleukin-1β 
exported from activated platelets [52]. Thus, PMVs 
are likely to contribute to the previously reported 
ability of activated platelets to induce 
monocyte-platelet and monocyte-endothelial 
interactions through secretion of monocyte 
chemotactic protein-1 by endothelia and monocytes as 
well as endothelial surface expression of ICAM-1, a 
counter-receptor for leukocyte Mac-1 [53,54]. In 
accordance with the this concept, Ueba et al. [55] 
observed an association of PMVs, identified on the 
basis of CD42-positivity, with interleukin-6 levels in 
healthy subjects.  
Notably, Mause et al. [56] demonstrated that the 
expression of both GPIb (CD42(b)) and P-selectin 
(CD62P) on the surface of PMVs was required for 
PMVs interactions with activated endothelial cells, 
including PMVs rolling and adhesion, deposition of 
PMVs-derived RANTES (Regulated on Activation, 
Normal T cell Expressed and Secreted) on endothelial 
surface and the PMVs-dependent monocyte 
recruitment to activated endothelium. In our CAD 
patients receiving ticagrelor, 3-6-lower plasma counts 
of CD42/CD62P-double positive and CD42-positive 
PMVs were observed compared to subjects on 
clopidogrel, regardless of platelet aggregability.  
So, it does not seem implausible to assume that 
markedly depressed counts of PMVs in patients on 
ticagrelor might be not only an epiphenomenon, 
accompanying strong and constant platelet inhibition 
in vivo, but – more importantly – can also represent a 
novel mechanism of the anti-inflammatory effect of 
the drug, with a possible contribution of endogenous 
adenosine accumulation [6,47]. Ticagrelor, inhibiting 
cellular adenosine uptake, was shown to augment 
vascular and platelet effects of exogenous adenosine, 
including its vasodilatory [57] and anti-aggregatory 
[58] effects. Notably, some of pleiotropic effects of 
ticagrelor may be at least partially ascribed to 
endogenous adenosine, such as enhancement of 
cardiac reactive hyperemia [59], anti-inflammatory 
activity (at high adenosine levels, contrary to 
pro-inflammatory effects of low adenosine [60]), as 
well as better outcome in patients with pulmonary 
infection [61], prevention of cardiac 
ischemia/reperfusion injury [62], and improvement 
of endothelial function [44].  
Whether the ticagrelor-associated reductions of 
PMVs generation might contribute to proposed 
anti-inflammatory and anti-atherosclerotic effects of 
the drug with prognostic implications in CAD 
patients, remains to be investigated in a randomized 
prospective study.  
Limitations of the study 
A small number of study subjects is a major 
limitation of our preliminary observational report. 
However, there were no intergroup differences in 
clinical characteristics, medication or hospitalization 
length. In particular, all the patients were on statins, 
known to affect PMVs counts [63]. Additionally, in 
order to reduce the heterogeneity of the study 
patients, we had excluded subjects with a history of 
previous ACS, coronary revascularization or DAPT, a 
complicated clinical course, coexistent diseases or 
relevant abnormalities in routine blood and urine 
assays.  
Second, blood samples were centrifuged once at 
2700 g for 10 min and then frozen until PMVs 
enumeration, while double centrifugation (2 x 15 min 
at 2500 g) is recommended to remove residual 
platelets which persist after a single centrifugation 
and may release MVs or fragment during a 
freeze-thaw cycle [64,65]. In our hands, to remove 
residual platelets from stored plasma, a second 
centrifugation (15 min at 2500 g) was carried out after 
thawing the sample, before flow cytometry analysis. 
Keeping in mind the importance of pre-analytical 
steps for PMVs assay [64-66], an additional analysis 
was done in order to compare the effects of 
inter-protocol differences on the concentration of 
residual platelets. We were able to demonstrate that 
the content of residual platelets in the plasma 
prepared using the recommended protocol [64,65] 
and that obtained by our procedure was similar under 
the condition that a second centrifugation was 
performed after thawing the frozen samples, as in our 
protocol (Supplementary Table S1). 
Third, we used CD42(b) (GPIb) to define PMPs 
by flow cytometry, similar to previous studies 
enumerating PMVs exposing CD42(b) and/or 
CD42(a) (GPIX) [16,18,27,29,55,67]. However, other 
criteria for PMVs identification were also reported, 
including the positivity for CD41 (GPIIb) [64] or CD61 
(GPIIIa) [15,17,19]. Additionally, Rank et al. [68] even 
suggested that a considerable portion of 
CD41-positive MVs, in contrast to CD62P-positive 
MVs, probably originates from megakaryocytes, not 
from platelets, which could also occur for GPIb [69]. 
Nevertheless, that we observed associations of ex vivo 
platelet reactivity only with plasma counts of 
CD42+/CD62P+ MVs, but not CD42+ or annexin V+ 
MVs, strongly suggests activated platelets as the 
predominant source of CD42+/CD62P+ MVs. 
Accordingly, the lack of association between 
CD42+/CD62P+ counts and the ADP-induced platelet 
aggregation in patients on ticagrelor, but not on 
thienopyridine P2Y12 ADP receptor antagonists, 
argues in favor of a ticagrelor-specific effect, i.e. a 
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dissociation of the drug-induced inhibition of in vivo 
PMVs release and ex vivo ADP-induced platelet 
aggregation. That platelet reactivity was attenuated to 
a similar degree in subjects treated with prasugrel and 
ticagrelor, also supports the proposed hypothetical 
concept.  
Fourth, we observed much higher numbers of 
CD42-positive than CD42/CD62P double-positive 
PMVs, which was rather unexpected keeping in mind 
the notion of PMVs generation during platelet 
activation, associated with surface CD62P expression. 
Nonetheless, Kafian et al. [18] reported 
CD62P-positivity on less than a half of plasma PMVs, 
defined on the basis of surface GPIX (CD42(a)) 
expression, which points into a relevant contribution 
of MVs shed from non-activated platelets to total 
PMVs release in vivo. Moreover, in agreement with 
our finding, Gąsecka et al. [19], studying in vitro 
platelet suspensions, described about 15-fold higher 
release of CD61+/CD62P−/PS− PMVs than 
CD61+/CD62P+/PS+ PMVs from suspensions of 
resting platelets, putatively reflecting MVs generation 
by non-activated and activated platelets, respectively. 
Intriguingly, unlike Gąsecka et al. [19], who reported 
the ability of ticagrelor (1 μmol/L) to inhibit the 
release of CD62P-positive, but not CD62P-negative 
PMVs in response to ADP, we observed lower plasma 
counts of PMVs in patients receiving ticagrelor, 
irrespective of CD62P-positivity. Nevertheless, 
comparisons between these reports are profoundly 
hampered by differences in study design and distinct 
criteria for the identification of PMVs by flow 
cytometry.  
Conclusions 
Higher antiplatelet potency of prasugrel and 
ticagrelor versus clopidogrel is associated with 
decreased plasma counts of CD42+/CD62P+ PMVs, 
originating presumably from activated platelets. 
However, in contrast to thienopyridines, the 
association of reduced CD42+/CD62P+ PMVs 
numbers with ticagrelor use appears independent of 
its anti-aggregatory effect. Notably, despite similar 
antiplatelet activity of ticagrelor and prasugrel, only 
the treatment with ticagrelor seems to be associated 
with lower counts of CD42+ PMVs, putatively 
reflecting total PMVs release. Thus, inasmuch as 
PMVs can contribute to CV risk, our preliminary 
findings may suggest a novel pleiotropic effect of 
ticagrelor extending beyond pure anti-aggregatory 
properties of the drug.  
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